GHDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Genomic Health Inc's research and development for the three months ended in Sep. 2016 was $15.1 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2016 was $59.0 Mil.
This is the expense the company spent on research and development.
Genomic Health Inc Research & Development for the trailing twelve months (TTM) ended in Sep. 2016 was 12.605 (Dec. 2015 ) + 15.963 (Mar. 2016 ) + 15.325 (Jun. 2016 ) + 15.109 (Sep. 2016 ) = $59.0 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Genomic Health Inc Annual Data
|Research & Development||12.8||22.1||28.6||35.7||33.2||39.9||49.1||66.3||56.1||59.8|
Genomic Health Inc Quarterly Data
|Research & Development||13.3||14.7||13.3||19.1||14.6||13.5||12.6||16.0||15.3||15.1|